157 related articles for article (PubMed ID: 35671066)
1. Systematic HIV-1 promoter targeting with CRISPR/dCas9-VPR reveals optimal region for activation of the latent provirus.
Klinnert S; Chemnitzer A; Rusert P; Metzner KJ
J Gen Virol; 2022 Jun; 103(6):. PubMed ID: 35671066
[TBL] [Abstract][Full Text] [Related]
2. Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9.
Olson A; Basukala B; Lee S; Gagne M; Wong WW; Henderson AJ
Viruses; 2020 Oct; 12(10):. PubMed ID: 33053801
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs.
Zhang Y; Yin C; Zhang T; Li F; Yang W; Kaminski R; Fagan PR; Putatunda R; Young WB; Khalili K; Hu W
Sci Rep; 2015 Nov; 5():16277. PubMed ID: 26538064
[TBL] [Abstract][Full Text] [Related]
4. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.
Saayman SM; Lazar DC; Scott TA; Hart JR; Takahashi M; Burnett JC; Planelles V; Morris KV; Weinberg MS
Mol Ther; 2016 Mar; 24(3):488-98. PubMed ID: 26581162
[TBL] [Abstract][Full Text] [Related]
5. Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies.
Darcis G; Das AT; Berkhout B
Viruses; 2018 Mar; 10(4):. PubMed ID: 29596334
[TBL] [Abstract][Full Text] [Related]
6. Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter.
Ji H; Jiang Z; Lu P; Ma L; Li C; Pan H; Fu Z; Qu X; Wang P; Deng J; Yang X; Wang J; Zhu H
Mol Ther; 2016 Mar; 24(3):508-21. PubMed ID: 26775808
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
8. Targeted shock-and-kill HIV-1 gene therapy approach combining CRISPR activation, suicide gene tBid and retargeted adenovirus delivery.
Klinnert S; Schenkel CD; Freitag PC; Günthard HF; Plückthun A; Metzner KJ
Gene Ther; 2024 Mar; 31(3-4):74-84. PubMed ID: 37558852
[TBL] [Abstract][Full Text] [Related]
9. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-mediated Activation of Latent HIV-1 Expression.
Limsirichai P; Gaj T; Schaffer DV
Mol Ther; 2016 Mar; 24(3):499-507. PubMed ID: 26607397
[TBL] [Abstract][Full Text] [Related]
11. Targeted Modulation of Chicken Genes In Vitro Using CRISPRa and CRISPRi Toolkit.
Chapman B; Han JH; Lee HJ; Ruud I; Kim TH
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107664
[TBL] [Abstract][Full Text] [Related]
12. Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems.
Bialek JK; Dunay GA; Voges M; Schäfer C; Spohn M; Stucka R; Hauber J; Lange UC
PLoS One; 2016; 11(6):e0158294. PubMed ID: 27341108
[TBL] [Abstract][Full Text] [Related]
13. A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures.
Wang G; Zhao N; Berkhout B; Das AT
Cell Rep; 2016 Dec; 17(11):2819-2826. PubMed ID: 27974196
[TBL] [Abstract][Full Text] [Related]
14. Repression of HIV-1 reactivation mediated by CRISPR/dCas9-KRAB in lymphoid and myeloid cell models.
da Costa LC; Bomfim LM; Dittz UVT; Velozo CA; da Cunha RD; Tanuri A
Retrovirology; 2022 Jun; 19(1):12. PubMed ID: 35733180
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-assisted transcription activation by phase-separation proteins.
Liu J; Chen Y; Nong B; Luo X; Cui K; Li Z; Zhang P; Tan W; Yang Y; Ma W; Liang P; Songyang Z
Protein Cell; 2023 Dec; 14(12):874-887. PubMed ID: 36905356
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas based antiviral strategies against HIV-1.
Wang G; Zhao N; Berkhout B; Das AT
Virus Res; 2018 Jan; 244():321-332. PubMed ID: 28760348
[TBL] [Abstract][Full Text] [Related]
17. A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes.
Huang Z; Nair M
Sci Rep; 2017 Jul; 7(1):5955. PubMed ID: 28729655
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
19. A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents
Matsuda K; Islam S; Takada T; Tsuchiya K; Yang Tan BJ; Hattori SI; Katsuya H; Kitagawa K; Kim KS; Matsuo M; Sugata K; Delino NS; Gatanaga H; Yoshimura K; Matsushita S; Mitsuya H; Iwami S; Satou Y; Maeda K
Cell Rep Methods; 2021 Dec; 1(8):100122. PubMed ID: 35475215
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-Mediated Activation of Endogenous Gene Expression in the Postnatal Heart.
Schoger E; Carroll KJ; Iyer LM; McAnally JR; Tan W; Liu N; Noack C; Shomroni O; Salinas G; Groß J; Herzog N; Doroudgar S; Bassel-Duby R; Zimmermann WH; Zelarayán LC
Circ Res; 2020 Jan; 126(1):6-24. PubMed ID: 31730408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
